FrancophonIA/ELRC3.0 huggingface dataset:
English: A multi-centre, randomised, double-blind, placebo-controlled Phase 3 study (PARAMOUNT), compared the efficacy and safety of continuation maintenance treatment with pemetrexed plus BSC (N = 359) with that of placebo plus BSC (N = 180) in patients with locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC other than predominantly squamous cell histology who did not progress after 4 cycles of first-line doublet therapy of pemetrexed in combination with cisplatin.
Croatian: U multicentričnom, randomiziranom, dvostruko slijepom, placebom kontroliranom ispitivanju faze 3 (PARAMOUNT) uspoređivala se djelotvornost i sigurnost kontinuiranog liječenja održavanja pemetreksedom uz BSC (n = 359) s onima primjene placeba uz BSC (n = 180) u bolesnika s lokalno uznapredovalim (stadij IIIB) ili metastatskim (stadij IV) NSCLC-om kod kojeg histološki ne prevladavaju pločaste stanice u kojih nije došlo do progresije nakon 4 ciklusa prve linije dvojne terapije pemetreksedom u kombinaciji s cisplatinom.Od 939 bolesnika liječenih uvodnom terapijom pemetreksedom i cisplatinom, 539 bolesnika randomizirano je u skupinu koja je primala terapiju održavanja pemetreksedom ili placebo.
English: Side effects with Pemetrexed Fresenius Kabi may include:
Croatian: Moguće nuspojave lijeka Pemetrexed Fresenius Kabi su:
English: Patients with renal impairment (Standard Cockcroft and Gault formula or Glomerular Filtration Rate measured Tc99m-DPTA serum clearance method): Pemetrexed is primarily eliminated unchanged by renal excretion.
Croatian: Bolesnici s oštećenjem bubrega (serumski klirens izračunat standardnom Cockcroftovom i Gaultovom formulom ili metodom mjerenja brzine glomerularne filtracije Tc99m-DPTA)
English: A multicentre, randomised, open label phase 3 study of pemetrexed versus docetaxel in patients with locally advanced or metastatic NSCLC after prior chemotherapy has shown median survival times of 8.3 months for patients treated with pemetrexed (Intent To Treat population n = 283) and 7.9 months for patients treated with docetaxel (ITT n = 288).
Croatian: U multicentričnom, randomiziranom, otvorenom ispitivanju faze 3 primjene pemetrekseda naspram docetaksela u bolesnika s lokalno uznapredovalim ili metastatskim NSCLC-om nakon prethodne kemoterapije medijan preživljenja bolesnika liječenih pemetreksedom iznosio je 8,3 mjeseca (populacija predviđena za liječenje, engl.
English: Each vial contains 100 mg of pemetrexed (as pemetrexed diacid).
Croatian: Jedna bočica sadrži 100 mg pemetrekseda (kao dikiselina).
English: Including the induction phase the median OS for patients with NSCLC other than predominantly squamous cell histology was 18.6 months for the pemetrexed arm and 13.6 months for the placebo arm, hazard ratio = 0.71 (95% CI = 0.56-0.88, p = 0.002).
Croatian: Uključujući fazu uvodnog liječenja, medijan ukupnog preživljenja u bolesnika s NSCLC-om kod kojeg histološki ne prevladavaju pločaste stanice bio je 18,6 mjeseci u skupini koja je primala pemetreksed te 13,6 mjeseci u skupini koja je primala placebo, omjer hazarda = 0,71 (95% CI = 0,56-0,88, p = 0,002).
English: Nadir platelets < 50,000/mm with bleeding a,
Croatian: Najniži broj trombocita < 50 000/mm3 uz krvarenjea, bez obzira na najniži ABN
English: The median OS for patients with NSCLC other than predominantly squamous cell histology (n = 481) was 15.5 months for the pemetrexed arm and 10.3 months for the placebo arm, hazard ratio = 0.70 (95% CI = 0.56-0.88, p = 0.002).
Croatian: Medijan ukupnog preživljenja u bolesnika s NSCLC-om kod kojeg histološki ne prevladavaju pločaste stanice (n = 481) bio je 15,5 mjeseci u skupini koja je primala pemetreksed i 10,3 mjeseca u skupini koja je primala placebo, omjer hazarda = 0,70 (95% CI = 0,56-0,88, p = 0,002).
English: How to store Pemetrexed Fresenius Kabi
Croatian: Kako čuvati lijek Pemetrexed Fresenius Kabi
English: Pemetrexed + cisplatin
Croatian: p-vrijednost za superiornost pemetreksed + cisplatin gemcitabin + cisplatin
English: Binding was not notably affected by varying degrees of renal impairment.
Croatian: Različiti stupnjevi poremećaja funkcije bubrega nisu znatnije utjecali na vezivanje lijeka.
English: The independent review of patient scans confirmed the findings of the investigator assessment of PFS. For randomised patients, as measured from the start of pemetrexed plus cisplatin first line induction treatment, the median investigator-assessed PFS was 6.9 months for the pemetrexed arm and 5.6 months for the placebo arm (hazard ratio = 0.59 95% CI =
Croatian: Prema procjeni ispitivača medijan PFS-a randomiziranih bolesnika, mjeren od početka prve linije uvodnog liječenja pemetreksedom i cisplatinom, iznosio je 6,9 mjeseci za skupinu koja je primala pemetreksed i 5,6 mjeseci za skupinu s placebom (omjer hazarda = 0,59 95% CI = 0,47-0,74).
English: Progression-free survival (months) ▪ Median ▪ HR (95% CI)
Croatian: Preživljenje (mjeseci) ▪ medijan (m) ▪ 95% CI za medijan
English: Clinically relevant CTC toxicities that were reported in ≥ 1 % and < 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: renal failure, infection, pyrexia, febrile neutropenia, increased AST, ALT, and GGT, urticaria and chest pain.
Croatian: Među klinički značajne oblike toksičnosti prema CTC kriterijima, prijavljene u ≥ 1% i ≤ 5% bolesnika randomiziranih u skupinu koja je primala cisplatin i pemetreksed, ubrajaju se: zatajenje bubrega, infekcija, pireksija, neutropenijska vrućica, povišene vrijednosti AST-a, ALT-a i GGT-a, urtikarija i bol u prsištu.
English: Clinically relevant toxicity that was reported in ≥ 1% and ≤ 5% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease.
Croatian: Među klinički značajne oblike toksičnosti prema CTC kriterijima, prijavljene u ≥ 1% i ≤ 5% bolesnika randomiziranih u skupinu koja je primala cisplatin i pemetreksed ubrajaju se: povišene vrijednosti AST-a, povišene vrijednosti ALT-a, infekcija, neutropenijska vrućica, zatajenje bubrega, pireksija, dehidracija, konjunktivitis i smanjen klirens kreatinina.
English: These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of ≥CTC Grade 2 bleeding.
Croatian: 100% prethodne doze a Zajednički kriteriji toksičnosti Nacionalnog instituta za rak (CTC v2.0; NCI 1998) b Osim neurotoksičnosti
English: In patients treated for non-small cell lung cancer after prior chemotherapy, the recommended dose of Pemetrexed Fresenius Kabi is 500 mg/m
Croatian: U 64 bolesnika s malignim pleuralnim mezoteliomom koji prethodno nisu primali kemoterapiju pemetreksedom on je ispitan u dozi od 500 mg/m2 u monoterapiji.
English: Chemical and physical in-use stability of reconstituted solutions of pemetrexed was demonstrated for 24 hours at refrigerated temperature.
Croatian: Rekonstituirana otopina pemetrekseda kemijski je i fizikalno stabilna 24 sata kada se čuva u hladnjaku.
English: Each vial contains 500 mg of pemetrexed (as pemetrexed diacid).
Croatian: Jedna bočica sadrži 500 mg pemetrekseda (kao dikiselina).
English: Pemetrexed/ cisplatin (N = 839)
Croatian: Pemetreksed/ cisplatin (N = 839)
English: Breastfeeding must be discontinued during Pemetrexed Fresenius Kabi treatment.
Croatian: Tijekom liječenja lijekom Pemetrexed Fresenius Kabi dojenje se mora prekinuti.
English: Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion
Croatian: Pemetrexed Fresenius Kabi 100 mg prašak za koncentrat za otopinu za infuziju
English: Reconstitute 100-mg vials with 4.2 ml of 5% glucose intravenous infusion resulting in a solution containing 25 mg/ml pemetrexed.
Croatian: Bočice od 100 mg rekonstituirajte s 4,2 ml 5% otopine glukoze za intravensku infuziju, čime se dobiva otopina koja sadrži 25 mg/ml pemetrekseda.
English: Reconstitute each 500 mg vial with 20 ml of 5% glucose intravenous infusion resulting in a solution containing 25 mg/ml pemetrexed.
Croatian: Svaku bočicu od 500 mg rekonstituirajte s 20 ml 5% otopine glukoze za intravensku infuziju, čime se dobiva otopina koja sadrži 25 mg/ml pemetrekseda.
English: Reconstitute each 100 mg vial with 4.2 ml of 5% glucose intravenous infusion resulting in a solution containing 25 mg/ml pemetrexed.
Croatian: Svaku bočicu od 100 mg rekonstituirajte s 4,2 ml 5% otopine glukoze za intravensku infuziju, čime se dobiva otopina koja sadrži 25 mg/ml pemetrekseda.
English: Inflammation of the lining of the oesophagus (gullet) has been experienced with Pemetrexed Fresenius Kabi / radiation therapy.
Croatian: Kod primjene lijeka Pemetrexed Fresenius Kabi / terapije zračenjem prijavljena je upala sluznice jednjaka (ezofagusa).
English: Reconstitute 500-mg vials with 20 ml of 5% glucose intravenous infusion resulting in a solution containing 25 mg/ml pemetrexed.
Croatian: Bočice od 500 mg rekonstituirajte s 20 ml 5% otopine glukoze za intravensku infuziju, čime se dobiva otopina koja sadrži 25 mg/ml pemetrekseda.
English: Breastfeeding
Croatian: Docetaksel
English: Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion
Croatian: Pemetrexed Fresenius Kabi 500 mg prašak za koncentrat za otopinu za infuziju
English: The recommended dose of cisplatin is 75 mg/m
Croatian: Preporučena doza cisplatina je 75 mg/m2 tjelesne površine, a primjenjuje se infuzijom u trajanju od dva sata,
English: Pemetrexed Fresenius Kabi as single agent
Croatian: Pemetrexed Fresenius Kabi
English: Due to the increased thrombotic risk in patients with cancer, the use of anticoagulation treatment is frequent.
Croatian: Interakcije koje su zajedničke svim citotoksičnim lijekovima Zbog povećanog rizika od tromboze onkološki se bolesnici često liječe antikoagulansima.
English: Constipation Stomatitis/
Croatian: Zatajenje bubrega
English: Nadir ANC < 500 /mm and nadir platelets
Croatian: Najniži ABN < 500 /mm3 i najniži broj trombocita  50 000 /mm3
English: Immune mediated haemolytic anaemia (antibody-mediated destruction of red blood cells) Hepatitis (inflammation of the liver)
Croatian: Intersticijski pneumonitis (stvaranje ožiljaka na mjehurićima u plućima (alveolama))
English: Fatigue (tiredness)
Croatian: Hepatitis (upala jetre)
English: Nausea
Croatian: Umor
English: Vomiting
Croatian: Cisplatin
English: Time to treatment failure (TTTF - months) ▪ Median ▪ HR (95% CI)
Croatian: Log-rang p-vrijednost* Vrijeme do prestanka odgovora na liječenje (mjeseci) (95% CI)
English: Common Vomiting Mucositis/ stomatitis
Croatian: Cisplatin Pemetreksed/ cisplatin
English: 19 January 2017 EMA/747766/2016
Croatian: EMA/747766/2016
English: • If you have any questions about your treatment, speak to your healthcare professional.
Croatian: • Ako imate pitanja o liječenju, obratite se svojem zdravstvenom radniku.
English: Measures intended to reduce risk of confusion between two pens of different strengths
Croatian: Mjere za smanjenje rizika zabune između dviju brizgalica različite jačine
English: Your healthcare professional will give you this information.
Croatian: Te će vam informacije pružiti vaš zdravstveni radnik.
English: This could lead to fluctuations in blood glucose control.
Croatian: To bi moglo dovesti do fluktuacije razine glukoze u krvi.
English: More information about Suliqua can be found on the Agency's website: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004243/human_ med_002064.jsp
Croatian: Više informacija o lijeku Suliqua nalazi se na internetskim stranicama Agencije: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004243 /human_med_002064.jsp
English: Information for patients and carers
Croatian: Informacije za bolesnike i njegovatelje
English: • Ensure that patients and their caretakers are adequately informed on how to use their medicine.
Croatian: • Pobrinite se da pacijenti i njihovi njegovatelji budu odgovarajuće obaviješteni o načinu primjene lijeka.
English: • You must therefore not use the pens interchangeably as you could receive too much or too little lixisenatide and this could disrupt the control of your blood sugar levels.
Croatian: • Stoga brizgalice ne smijete koristiti naizmjenično jer biste mogli primiti previše ili premalo liksisenatida, što bi moglo poremetiti vašu razinu šećera u krvi.
English: Patients will receive a ‘patient guide' from their healthcare professional which they should read carefully along with the package leaflet.
Croatian: Pacijenti će od zdravstvenih radnika primiti „vodič za pacijente” koji trebaju pažljivo pročitati zajedno s uputom o lijeku.
English: • When starting Suliqua and in the weeks thereafter you should measure your blood sugar levels more frequently than usual.
Croatian: • Kada počnete primjenjivati lijek Suliqua i u tjednima nakon toga, trebate provjeravati razinu šećera u krvi češće nego inače.
English: It is available as a solution for injection in pre-filled pens.
Croatian: Lijek je dostupan kao otopina za injekciju u napunjenim brizgalicama.
English: To reduce the risk of medication errors, educational materials will be sent out to relevant healthcare professionals in the EU where the product is marketed, to raise awareness about the differences between the two pens, the way the dose is expressed and how to use the medicine correctly.
Croatian: Kako bi se spriječio rizik od pogrešaka u doziranju, edukativni materijali bit će poslani relevantnim zdravstvenim radnicima na području EU-a u kojem se proizvod stavlja na tržište kako bi se podigla svijest o razlikama između dviju brizgalica, o načinu određivanja doze i ispravnoj primjeni lijeka.
English: Suliqua is a medicine that is used for the treatment of type-2 diabetes.
Croatian: Suliqua je lijek koji se koristi za liječenje dijabetesa tipa
English: • Patients who are blind or with poor vision must be instructed to always get assistance from another person who has good vision and is trained in using the Suliqua pen device.
Croatian: • Slijepim ili slabovidnim bolesnicima mora se objasniti da uvijek zatraže pomoć druge osobe koja ima dobar vid i koja je obučena za primjenu brizgalice s lijekom Suliqua.
English: You must never use a syringe to remove the medicine from its pen as this may lead to dosing errors and serious harm.
Croatian: Nikada ne smijete koristiti štrcaljku kako biste lijek izvukli iz brizgalice jer to može dovesti do pogreške u doziranju i ozbiljne štete.
English: It is used together with diabetes medicines taken by mouth in adults whose blood glucose (sugar) levels are not satisfactorily controlled by metformin alone or metformin combined with either a glucose-lowering medicine or insulin.
Croatian: Koristi se zajedno s lijekovima za liječenje dijabetesa koji se primjenjuju peroralno u odraslih osoba čije se razine glukoze (šećera) u krvi ne mogu kontrolirati na zadovoljavajući način samo metforminom ili metforminom u kombinaciji s lijekom za smanjenje razine glukoze ili inzulinom.
English: It is used for people needing 10-40 units of insulin daily.
Croatian: Koristi se u bolesnika koji trebaju 10 do 40 jedinica inzulina dnevno.
English: • Tell patients to closely monitor their blood sugar levels when starting Suliqua and in the weeks thereafter.
Croatian: • Uputite bolesnike da pozorno prate razine šećera u krvi na početku primjene lijeka Suliqua i u tjednima nakon toga.
English: Healthcare professionals and patients expected to use the diabetes medicine Suliqua will be given educational materials to ensure that the medicine is used correctly and prevent medication errors such as confusion between the two different strengths of the product.
Croatian: Zdravstveni radnici i bolesnici za koje se očekuje da će koristiti lijek za dijabetes Suliqua dobit će edukativne materijale kako bi se zajamčila ispravna primjena lijeka i spriječile pogreške u doziranju lijeka kao što je zabuna između dviju različitih jačina proizvoda.
English: Before you use Suliqua be clear on how many dose steps you require.
Croatian: Prije uporabe lijeka Suliqua provjerite koliko vam je prirasta doze potrebno.
English: Healthcare professionals should ensure that they train their patients on how to use Suliqua correctly.
Croatian: Zdravstveni radnici trebaju obučiti svoje pacijente kako ispravno primjenjivati lijek Suliqua.
English: Pharmacists should also check that patients have been trained on how to use the pen.
Croatian: Ljekarnici bi također trebali provjeriti jesu li bolesnici obučeni za primjenu brizgalice.
English: • Suliqua is a fixed combination of insulin glargine/lixisenatide available in two strengths:
Croatian: • Suliqua je fiksna kombinacija inzulina glargina i liksisenatida dostupna u dvije jačine:
English: • As for similar medicines containing insulin with a non-insulin medicine, the dose is expressed in dose steps.
Croatian: • Kao i kod sličnih lijekova koji sadrže inzulin i neinzulinski lijek, doza se izražava u prirastu doze.
English: The doses of insulin and lixisenatide contained in increasing dose steps are given in the figure below:
Croatian: Doze inzulina i liksisenatida koje se nalaze u rastućim prirastima doze nalaze se u nastavku:
English: • Because the two pens contain different concentrations of lixisenatide, the dose step of one pen is not equivalent to the dose step of the other.
Croatian: • Budući da te dvije brizgalice sadrže različitu koncentraciju liksisenatida, prirast doze jedne brizgalice nije jednak prirastu doze druge brizgalice.
English: • Pharmacists are encouraged to check that patients and carers are able to read the strength of Suliqua, the dose range of the pre-filled pen and the dose counter of the pen device before dispensing Suliqua.
Croatian: • Ljekarnicima se preporučuje da provjere mogu li bolesnici i njegovatelji pročitati jačinu lijeka Suliqua, raspon doze napunjene brizgalice te očitati brojač doza na brizgalici prije doziranja lijeka Suliqua.
English: The amount of lixisenatide per dose step however varies (0.50 micrograms per dose step for the 10-40 pen and 0.33 micrograms per dose step for the 30-60 pen).
Croatian: Međutim, razlikuje se količina liksisenatida po prirastu doze (0,50 mikrograma po prirastu doze za brizgalicu 10-40 i 0,33 mikrograma po prirastu doze za brizgalicu 30-60).
English: • Suliqua is supplied in a pre-filled pen and must only be used with this device.
Croatian: • Suliqua se isporučuje u napunjenoj brizgalici te se treba upotrebljavati samo s tom napravom.
English: Suliqua is available in two different pens:
Croatian: Lijek Suliqua dostupan je u dvije različite brizgalice:
English: As for similar combination medicines used for the treatment of diabetes, the dose of Suliqua is expressed in ‘dose steps', with each dose step corresponding to one unit of insulin plus a fixed amount of lixisenatide.
Croatian: Kao i kod sličnih kombinacija lijekova koje se koriste za liječenje dijabetesa, doza lijeka Suliqua određuje se u „prirastu doze”, pri čemu svaki prirast doze odgovara jednoj jedinici inzulina i fiksnoj količini liksisenatida.
English: A syringe must never be used to withdraw insulin glargine and lixisenatide from the pre-filled pen as this may lead to dosing errors and serious harm.
Croatian: Za izvlačenje inzulina glargina i liksisenatida iz napunjene brizgalice nikada se ne smije koristiti štrcaljka jer to može dovesti do pogrešaka u doziranju i ozbiljne štete.
English: One dose step always contains one unit of insulin, regardless of the Suliqua pen being used.
Croatian: Jedan prirast doze uvijek sadrži jednu jedinicu inzulina, bez obzira na to koja se brizgalica lijeka Suliqua koristi.
English: Your healthcare professional will train you on how to use the pen.
Croatian: Zdravstveni radnik objasnit će vam kako trebate upotrebljavati brizgalicu.
English: • Suliqua is supplied in two pre-filled pens:
Croatian: • Suliqua se isporučuje u dvije različite napunjene brizgalice:
English: deliver between 10 and 40 dose steps per day (and is also referred to as Suliqua 10-40).
Croatian: Ova brizgalica sadrži od 10 do 40 prirasta doze po danu (naziva se i Suliqua 10-40).
English: • Read the instructions in your package leaflet carefully before using your medicine.
Croatian: • Prije uporabe lijeka pažljivo pročitajte uputu o lijeku.
English: • Explain to your patient that the dose counter of the pen device shows the number of dose steps to be injected.
Croatian: • Objasnite bolesnicima da brojač doza na brizgalici prikazuje broj prirasta doza koje je potrebno injektirati.
English: • Suliqua is given in dose steps which correspond to a set number of units of insulin plus a fixed amount of lixisenatide.
Croatian: • Suliqua se primjenjuje u prirastima doze koji odgovaraju određenom broju jedinica inzulina i fiksnoj količini liksisenatida.
English: One dose step always contains one unit of insulin plus a fixed amount of lixisenatide.
Croatian: Jedan prirast doze uvijek sadrži jednu jedinicu inzulina i fiksnu količinu liksisenatida.
English: • Explain the design and features of the pen to the patient and if the patient has been transferred from another pen device, highlight the differences in design between the two devices to avoid confusion (focus on colour differentiation, warning statements on carton/label).
Croatian: Ako je bolesnik dosad koristio neku drugu napravu u obliku brizgalice, istaknite razlike u izgledu tih naprava kako bi se izbjegla zabuna (posebno istaknite razliku u boji, upozoravajuće izjave na pakiranju/etiketi).
English: The prescription must state the type of pen to be used (either Suliqua 10-40 or Suliqua 30-60), the strength (i.e. insulin glargine 100 units/ml + lixisenatide 50 micrograms/ml or insulin glargine 100 units/ml + lixisenatide 33 micrograms/ml) and the number of dose steps to be administered.
Croatian: Na receptu se mora navesti vrsta brizgalice koja se treba koristiti (Suliqua 10-40 ili Suliqua 30-60), jačina (tj. 100 jedinica/ml inzulina glargina + 50 mikrograma/ml liksisenatida ili 100 jedinica/ml inzulina glargina + 33 mikrograma/ml liksisenatida), kao i broj prirasta doze koje treba primijeniti.
English: • Suliqua must only be used with its pre-filled pen.
Croatian: • Suliqua se smije primjenjivati samo pomoću napunjene brizgalice.
English: The lixisenatide strength is lower to ensure an adequate but not excessive dose in people requiring higher doses of insulin.
Croatian: Jačina liksisenatida manja je kako bi se bolesnicima koji trebaju više doze inzulina pružila odgovarajuća, ali ne prevelika doza.
English: • The dose counter of the pen device shows the number of dose steps to be injected.
Croatian: • Brojač doza na brizgalici prikazuje broj prirasta doza koje je potrebno injektirati.
English: The lixisenatide strength is higher to ensure an adequate dose in people requiring lower doses of insulin.
Croatian: Jačina liksisenatida veća je kako bi se bolesnicima koji trebaju niže doze inzulina pružila odgovarajuća doza.
English: • Pharmacists should clarify with the prescriber any incomplete prescription.
Croatian: • Ako recept nije potpun, ljekarnici to trebaju razjasniti s liječnikom.
English: Suliqua contains a combination of insulin glargine and a non-insulin medicine, lixisenatide.
Croatian: Suliqua sadrži kombinaciju inzulina glargina i neinzulinskog lijeka liksisenatida.
English: deliver between 30 and 60 dose steps per day (and is also referred to as Suliqua 30-60) Since the two pens contain different amounts of lixisenatide for each dose step, it is important that they are not used interchangeably as this would result in patients receiving too much or too little lixisenatide.
Croatian: Budući da te dvije brizgalice sadrže različitu količinu liksisenatida u svakom prirastu doze, važno je da se ne koriste naizmjenično jer bi bolesnici mogli primiti previše ili premalo liksisenatida.
English: • Suliqua contains insulin glargine and a non-insulin medicine, lixisenatide.
Croatian: • Suliqua sadrži inzulin glargin i neinzulinski lijek liksisenatid.
English: • Provide patients with the patient guide prior to prescribing or dispensing Suliqua.
Croatian: • Prije nego što propišete ili izdate lijek Suliqua, pacijentu dajte vodič za pacijente.